Nasdaq Stockholm AB: The observation status for WeSC AB (publ) is removed (266/21)

On March 12, 2020, the shares in WeSC AB (publ) (the "Company") were given
observation status with reference to material adverse uncertainty in respect of
the Company's financial position. 

On March 22, 2021, Nasdaq Stockholm AB decided to update the observation status
on the grounds that the Company intended to acquire three different companies
and thus change its business. The acquisitions were conditional upon, inter
alia, approval by a general meeting of the Company's shareholders and Nasdaq
Stockholm AB's decision to admit the Company's shares to continued trading on
Nasdaq First North Growth Market. 

On May 11, 2021, the Company issued a press release with information that
Nasdaq Stockholm AB had approved the Company's shares for continued trading on
Nasdaq First North Growth Market. The decision was conditional upon the
Company's disclosure of a company description. 

On May 18, 2021, the Company issued a press release disclosing a company
description. According to the company description, the Company would upon
completion of the relevant acquisitions have working capital sufficient for
twelve months. 

On May 20, 2021, the Company issued a press release with information that an
annual general meeting of its shareholders had decided to approve the proposed
acquisitions and the funding of the acquisitions through several share issues. 

Today, June 2, 2021, the Company issued a press release with information that
the share issues funding the acquisitions had been registered. 

With reference to the above, Nasdaq Stockholm AB decides to remove the
observation status for the shares in WeSC AB (publ) (WESC, ISIN code
SE0014556718, order book ID 55316) with immediate effect. 

For further information concerning this exchange notice please contact Issuer
Surveillance, telephone [phone]. 

Nasdaq Stockholm AB

Elias Skog                                   
  Henrik Hammargren 

Head of Enforcement & Investigations               Regulatory
Compliance Specialist